Margaret MacLean

Margaret (Mandy) MacLean MBE FRSE is an expert in pulmonary pharmacology. She is renowned for her work on the role of sex effects and serotonin in metabolising oestrogen, also for identifying target enzymes for the treatment of pulmonary arterial hypertension. MacLean is currently a Professor of Pulmonary Pharmacology in the Strathclyde Institute of Pharmacy and Biomedical Sciences at the University of Strathclyde Glasgow.[1]

Margaret MacLean
Alma materPhD in Pharmacology from the University of Edinburgh - 1985
AwardsMBE - 2010

Fellow of The Royal Society of Edinburgh (FRSE) - 2013

British Pharmacological Society AstraZeneca Prize for Women in Pharmacology - 2013
Scientific career
FieldsPulmonary pharmacology
InstitutionsUniversity of Strathclyde, Glasgow

MacLean was awarded the MBE in the 2010 Queen’s New Year Honours list.[2] In 2013, MacLean was elected Fellow of The Royal Society of Edinburgh (FRSE) and received the British Pharmacological Society AstraZeneca Prize for Women in Pharmacology.[1] In 2018, she was made a Fellow of the Academy of Medical Sciences (FMedSci)[3] and was appointed Scottish Champion for the Academy of Medical Sciences[1] for her efforts in science communication.

References
  1. "Mandy MacLean — University of Strathclyde". pureportal.strath.ac.uk. Retrieved 2019-06-05.
  2. "The complete New Year Honours lists, 2010". 2009-12-31. Retrieved 2019-06-05.
  3. "Professor Margaret (Mandy) MacLean | The Academy of Medical Sciences". acmedsci.ac.uk. Retrieved 2019-06-05.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.